Found: 16
Select item for more details and to access through your institution.
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
- Published in:
- International Journal of COPD, 2019, v. 14, p. 2849, doi. 10.2147/COPD.S226601
- By:
- Publication type:
- Article
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 9, p. 3775, doi. 10.1007/s12325-020-01409-8
- By:
- Publication type:
- Article
Cheers to CVS for tobacco stand.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
The Hartford Hearing: Is United Listening?
- Published in:
- Rhode Island Medical Journal, 2014, v. 97, n. 2, p. 7
- By:
- Publication type:
- Article
“Decent respect”: An Update on United’s October Surprise.
- Published in:
- Rhode Island Medical Journal, 2013, v. 96, n. 12, p. 7
- By:
- Publication type:
- Article
United’s October Surprise.
- Published in:
- Rhode Island Medical Journal, 2013, v. 96, n. 11, p. 8
- By:
- Publication type:
- Article
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
- Published in:
- Pulmonary Therapy, 2021, v. 7, n. 1, p. 101, doi. 10.1007/s41030-020-00136-3
- By:
- Publication type:
- Article
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2020, p. 1, doi. 10.1177/1753466620963021
- By:
- Publication type:
- Article
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2020, p. 1, doi. 10.1177/1753466620963021
- By:
- Publication type:
- Article
A Call To Arms: Getting Involved In Advocacy.
- Published in:
- Medicine & Health Rhode Island, 2010, v. 93, n. 6, p. 175
- By:
- Publication type:
- Article
Physician Advocacy and the 2010 Health Care Reform Act.
- Published in:
- Medicine & Health Rhode Island, 2010, v. 93, n. 6, p. 168
- By:
- Publication type:
- Article
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article